Company / Cash & Equivalents
Prime Medicine, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$182.5M
FY2024
5-year range
$37.0M / $187.6M
FY2020-FY2024
Trend
+338.9%
vs FY2023
Sector context
#94 of 208
Health Care
What the data says
Cash & Equivalents changed +339% YoY in FY2024, a notable deviation from the 4-year average annual change of +166%.
Based on SEC 10-K filings.
$182M in FY2024 with a 3-year CAGR of -0.5%.
Declined from $188M to $182M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 208 in Health CareTop 45% of 208This company $182.5M Sector average $694.3M
▼
-73.7% below sector average
Key checks
Key Insights
- 3-year CAGR of -0.5%, indicating a declining trend.
- In FY2024, cash & equivalents increased 338.9% year-over-year.
- Ranks #94 out of 208 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $182.5M | +338.9% |
| FY2023 | $41.6M | -77.8% |
| FY2022 | $187.6M | +1.2% |
| FY2021 | $185.4M | +401.5% |
| FY2020 | $37.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026